Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement

Nontuberculous mycobacterial pulmonary diseases (NTM-PD) are increasingly recognised as opportunistic infections of humans. These chronic pulmonary infections have two main presentations. The first is a fibro-cavitary disease, that occurs in patients with pre-existing pulmonary diseases, such as chronic obstructive pulmonary disease, bronchiectasis, previous tuberculosis or other structural lung disease. The second presentation is a nodular-bronchiectatic disease of primarily the lingula and middle lobe that tends to affect a middle-aged and elderly female population [1]. Improving treatment outcome reporting in NTM disease: NTM-NET (@ntmnet) consensus statement on treatment outcome definitions http://ow.ly/c6IC30iwLM4

[1]  Marieke J. van der Werf,et al.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement , 2014, European Respiratory Journal.

[2]  D. Addrizzo-Harris,et al.  Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease , 2016, American journal of respiratory and critical care medicine.

[3]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[4]  R. Wallace,,et al.  Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease. , 2015, American journal of respiratory and critical care medicine.

[5]  D. Staab,et al.  Mental health in cystic fibrosis: turning the tide , 2015, Thorax.

[6]  D. van Soolingen,et al.  Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence , 2013, Expert review of anti-infective therapy.

[7]  C. Haworth,et al.  British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) , 2017, BMJ Open Respiratory Research.

[8]  F. van Leth,et al.  Treatment Outcomes in Multidrug-Resistant Tuberculosis. , 2016, The New England journal of medicine.

[9]  Nalin Rastogi,et al.  Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria , 2016, Clinical Microbiology Reviews.

[10]  G. Sotgiu,et al.  Good news about a bad subject: scientific evidence to help defeat multidrug/extensively drug-resistant tuberculosis , 2014, European Respiratory Journal.

[11]  P. Flume.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  C. Daley,et al.  Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection. A Prospective Cohort Study. , 2016, Annals of the American Thoracic Society.

[13]  W. Hoefsloot,et al.  Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. , 2017, Respiratory medicine.

[14]  J. Soar,et al.  BTS guideline for oxygen use in adults in healthcare and emergency settings , 2017, Thorax.

[15]  J. Stout,et al.  Update on pulmonary disease due to non-tuberculous mycobacteria. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[16]  K. Lee,et al.  Serial CT findings of nodular bronchiectatic Mycobacterium avium complex pulmonary disease with antibiotic treatment. , 2013, AJR. American journal of roentgenology.

[17]  G. Bloemberg,et al.  Diagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-time PCR Assays for Detection of Multiple Mycobacterial Pathogens With Line Probe Assays for Identification of Resistance Mutations , 2016, EBioMedicine.

[18]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.